![]() |
|
|
Vol. 27, Issue 6, 637-644, June 1999
Division of Drug Delivery and Disposition, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (X.L., E.L.L., K.L.R.B.); and Division of Bioanalysis and Drug Metabolism, Glaxo Wellcome, Inc., Research Triangle Park, North Carolina (J.P.C., K.R.B.)
| |
Abstract |
|---|
|
|
|---|
The relationship between biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats was examined. The biliary excretion of seven model substrates in 96-h sandwich-cultured rat hepatocytes was determined by differential cumulative uptake of substrate in the monolayers preincubated in standard buffer (intact bile canaliculi) and Ca2+-free buffer (disrupted bile canaliculi). Biliary excretion in vivo was quantitated in bile duct-cannulated rats. The biliary excretion index of model substrates, equivalent to the percentage of retained substrate in the canalicular networks, was consistent with the percentage of the dose excreted in bile from in vivo experiments. The in vitro biliary clearance of inulin, salicylate, methotrexate, [D-pen2,5]enkephalin, and taurocholate, calculated as the ratio of the amount excreted into the bile canalicular networks and the area under the incubation medium concentration-time profile (~0, ~0, 4.1 ± 1.0, 12.6 ± 2.2, and 56.2 ± 6.0 ml/min/kg, respectively), correlated with their intrinsic in vivo biliary clearance (0.04, 0, 17.3, 34.4, and 116.9 ml/min/kg, respectively; r2 = 0.99). The model compound 264W94 was not excreted in bile either in vivo or in vitro. The glucuronide conjugate of 2169W94, the O-demethylated metabolite of 264W94, was excreted into bile in vitro when 2169W94, but not 264W94, was incubated with the monolayers; 2169W94 glucuronide undergoes extensive biliary excretion after administration of 264W94 or 2169W94 in vivo. Biliary excretion in long-term sandwich-cultured rat hepatocytes correlates with in vivo biliary excretion. The study of biliary excretion of metabolites in the hepatocyte monolayers requires consideration of the status of metabolic activities.
| |
Introduction |
|---|
|
|
|---|
Many drugs undergo biliary
excretion, although the extent of secretion in bile often is difficult
to quantitate, particularly in humans. Alterations in biliary excretion
due to disease states or drug interactions may have important
pharmacologic and/or toxicologic implications. For example,
coadministration of antibiotics with drugs that undergo enterohepatic
recirculation may substantially inhibit enterohepatic recycling and
result in lower plasma concentrations and pharmacologic effects of the
affected drug (Parker et al., 1980
). This type of drug interaction has
been implicated in the failure of the oral contraceptive
ethinylestradiol (Shenfield, 1993
). Interactions in biliary excretion
are difficult to predict due to the lack of an optimal in vitro model
to evaluate and study biliary excretion.
The elucidation of biliary excretion properties of drug candidates is
also a critical issue in the drug discovery and development process.
Drug candidates that are extensively excreted into bile may never
achieve adequate concentrations in vivo. For example, many
metabolically stable peptides exhibit short residence times in the
systemic circulation (Greenfield et al., 1989
; Chen and Pollack, 1997
)
and low bioavailability after oral administration due to rapid and
extensive biliary excretion (Ziegler et al., 1985
; 1991
). Therefore,
knowledge of the extent of biliary excretion of drug candidates in the
early stages of drug development may be as important as absorption and
metabolic properties when selecting drug candidates.
Numerous in vivo (e.g., bile duct-cannulated animals) and in vitro
preparations (e.g., isolated perfused livers, isolated hepatocytes,
hepatocyte couplets, liver plasma membrane vesicles, and expressed
transport proteins) have been used to investigate biliary excretion
processes (Oude Elferink et al., 1995
). However, existing methods may
not always be applied to investigate human biliary excretion. In
addition, current approaches cannot be used to efficiently examine
biliary excretion processes for a large number of drug candidates.
Therefore, there is a tremendous need for a rapid and inexpensive in
vitro screening method that is predictive of hepatobiliary disposition
in animals and humans, especially in this modern era of high synthetic
capabilities (e.g., combinatorial chemistry approaches).
Long-term (more than 24 h) sandwich-cultured hepatocytes represent
a potential in vitro model to study biliary excretion. Previous work
has demonstrated that maintenance of hepatocytes in a collagen-sandwich
configuration prolongs cell viability and preserves liver-specific
protein synthesis (Dunn et al., 1989
; 1991
). Further studies showed
that long-term sandwich-cultured hepatocytes reestablish a structurally
and functionally normal bile canalicular network and show better
maintenance of drug uptake and enzyme-induction potential (Sidhu et
al., 1993
; Musat et al., 1993
; LeCluyse et al., 1996
). Recently, it has
been demonstrated that the expression and function of primary active
transporters, such as the sinusoidal
Na+/taurocholate-cotransporting polypeptide, the
canalicular bile acid transporter, and the canalicular-multispecific
organic anion transporter, were maintained in hepatocytes cultured in a
collagen-sandwich configuration for 96 to 120 h (Liu et al., 1998
;
1999a
).
The sandwich-cultured hepatocyte system is composed of two
compartments: cytosol and canalicular lumen. The tight junctional complex is the diffusional barrier between the canalicular lumen and
the extracellular space (LeCluyse et al., 1994
; Talamini et al., 1997
).
In this system, Ca2+ depletion increases tight
junction permeability and enables substrate translocation between the
canalicular and extracellular spaces based on favorable concentration
gradients (Liu et al., 1999a
). During cumulative uptake studies,
substrate in the medium was taken up by hepatocytes and excreted into
the bile canalicular networks. In standard buffer, the barrier function
of the tight junctions is intact and the excreted substrate is
localized in the canalicular compartment. In
Ca2+-free buffer, the barrier function of tight
junctions is disrupted and the substrate in the canalicular compartment
diffuses back into the incubation medium. Thus, in standard buffer, the
cumulative uptake of a substrate in the long-term sandwich-cultured
hepatocytes represents the amount of substrate in the cytosolic and
canalicular compartments; in Ca2+-free buffer,
the cumulative uptake represents substrate in the cytosolic
compartment. The amount of substrate secreted in the canalicular lumen,
i.e., the biliary excretion of substrates in the monolayers, can be
estimated from the difference in cumulative uptake in the presence and
absence of Ca2+. This method has been used to
quantitatively study hepatocyte polarization during the course of
culture (Liu et al., 1999a
). However, it remains to be
determined whether the estimates of biliary excretion based on this in
vitro model are consistent with in vivo biliary excretion data.
The objective of the present study was to examine the relationship between the estimated biliary excretion in the long-term sandwich-cultured hepatocytes and the extent of biliary excretion in vivo in rats. These results indicate that biliary excretion in rat hepatocytes cultured in a collagen-sandwich configuration for 96 h correlates with in vivo biliary excretion in rats.
| |
Materials and Methods |
|---|
|
|
|---|
Chemicals. [3H]Taurocholate (3.4 Ci/mmol; purity >97%), [14C]salicylate (55.5 mCi/mmol; purity >99%), and [3H][D-pen2,5]enkephalin (36 Ci/mmol; purity >97%) were obtained from DuPont-New England Nuclear (Boston, MA). [3H]Methotrexate (13.7 Ci/mmol; purity >99%) and [3H]inulin (1.3 Ci/mmol; purity >97%) were obtained from Amersham International plc (Buckinghamshire, England). Compounds [14C]264W94 [(3R, 5R)-3-butyl-3-ethyl-2, 3, 4, 5-tetrahydro-7, 8-dimethoxy-5-phenyl-1, 4-benzothiazepine-1, 1-dioxide; 45.5 mCi/mmol; purity >99%] and [14C]2169W94 [(3R, 5R)-3-butyl-3-ethyl-2, 3, 4, 5-tetrahydro-7-methoxy-8-hydroxy-5-phenyl-1, 4-benzothiazepine-1, 1-dioxide; 43.7 mCi/mmol; purity >99%] were obtained from Glaxo Wellcome, Inc. (Research Triangle Park, NC). Collagenase (type I, class I) was obtained from Worthington Biochemical Corp. (Freehold, NJ). Dulbecco's modified Eagle's medium (DMEM)1, fetal bovine serum, and insulin were purchased from Gibco (Grand Island, NY). Rat tail collagen (type I) was obtained from Collaborative Biomedical Research (Bedford, MA). All other chemicals and reagents were of analytical grade and were readily available from commercial sources.
Animals. Male Wistar rats (250-280 g), obtained from Charles River Laboratories, Inc. (Raleigh, NC), were used as liver donors. Rats were housed individually in stainless steel cages in a constant alternating 12-h light/dark cycle at least 1 week before the study was performed and were fed ad libitum until use. Bile duct-cannulated rats (200-250 g) were obtained from Charles River Laboratories, Inc. (Raleigh, NC). All procedures were approved by the Institutional Animal Care and Use Committee.
Preparation of Culture Dishes. Plastic culture dishes (60-mm) were precoated with rat tail collagen at least 1 day before preparing the hepatocyte cultures. To obtain a gelled collagen substratum, ice-cold neutralized collagen solution (0.1 ml, 1.5 mg/ml, pH 7.4) was spread onto each culture dish. Freshly coated dishes were placed at 37°C in a humidified incubator for approximately 1 h to allow the matrix material to gel, followed by addition of 3 ml DMEM to each dish and storage in a humidified incubator.
Culture of Rat Hepatocytes.
Hepatocytes were isolated with a two-step perfusion method as reported
previously (Liu et al., 1998
). Rats were anesthetized with ketamine and
xylazine (60 and 12 mg/kg i.p., respectively) before portal vein
cannulation. The liver was perfused in situ with oxygenated
Ca2+-free Krebs-Henseleit bicarbonate buffer
containing 5.5 mM glucose for 10 min at 37°C followed by perfusion
with Krebs-Henseleit bicarbonate buffer containing collagenase type I
(0.5 mg/ml) for 10 min. The hepatic capsule was removed with forceps.
The hepatocytes were released by shaking the liver gently in 100 ml
DMEM. The released cells were filtered through a sterile nylon mesh (70 µm). The hepatocyte suspensions were centrifuged at 50g
for 3 min. The cell pellet was resuspended in 25 ml DMEM and an equal volume of 90% isotonic Percoll (pH 7.4); the resulting cell suspension was centrifuged at 150g for 5 min. The pellet was
resuspended in 50 ml DMEM and the cell suspensions were combined into
one tube followed by centrifugation at 50g for 3 min.
Hepatocyte viability was determined by trypan blue exclusion. Only
those hepatocyte preparations with viability greater than 90% were
used for further studies. Hepatocyte suspensions were prepared with
DMEM containing 5% fetal calf serum, 1 µM dexamethasone and 4 mg/liter insulin. Hepatocyte suspensions were added to the precoated
dishes at a density of 2 × 106 cells/60-mm
dish. Approximately 1 h after plating the cells, the medium was
aspirated and 3 ml of fresh DMEM was added. For transport studies,
hepatocytes that had been seeded for 3 to 5 h without collagen
overlay were defined as 3-h or short-term cultured hepatocytes.
Cumulative Uptake Studies in Sandwich-Cultured Hepatocytes.
Hepatocytes cultured in a collagen-sandwich configuration were
incubated in 3 ml of standard buffer or Ca2+-free
buffer at 37°C for 10 min. After removing the incubation buffer,
uptake was initiated by addition of 3 ml of standard buffer containing
substrate to each dish. Substrate concentrations were selected in the
linear range based on preliminary studies or previously published data
(Liu et al., 1999b
). After incubation for designated times,
cumulative uptake was terminated by aspirating the incubation solution
and rinsing 4 times with 3 ml of ice-cold standard buffer to remove
extracellular substrate. After washing, 2 ml of 1% Triton X-100
solution was added to culture dishes and the cells were lysed by
shaking the dish on a shaker for 20 min at room temperature. An aliquot
(1 ml) of lysate was analyzed by liquid scintillation spectrometry.
Bio-Rad DC Protein Assay Kit (Bio-Rad Laboratories, Hercules, CA) was
used to determine the protein concentration in the culture extracts
using bovine serum albumin as standard. Triton X-100 (1%) did not
interfere with the assay. All values for substrate uptake into cell
monolayers were corrected for nonspecific binding to the collagen by
subtracting the substrate uptake determined in the appropriate control
dishes in the absence of cells as described previously (Liu et al.,
1998
). Nonspecific binding for a given substrate was consistent between
petri dishes.
Biliary Excretion in Rats after i.v. Administration of 264W94 and
Oral Administration of 2169W94.
[14C]264W94 was formulated as a solution in a
mixture of sterile water/polypropylene glycol 400/ethanol (2:1:1 v/v/v)
at a concentration of 0.125 mg/ml. After collection of predose bile,
[14C]264W94 solution was administered by caudal
vein injection (0.1 mg/kg). For the 2169W94 studies,
[14C]2169W94 was prepared as a
suspension at a concentration of 0.1 mg/ml in 0.5% (w/v)
methylcellulose in water. After collection of predose bile,
[14C]2169W94 suspension was
administrated by gavage (1.0 mg/kg). All rats were placed into
individual plastic metabolism cages that allowed the rats unrestrained
movement. Bile was collected into polypropylene containers surrounded
by ice. For the 264W94 studies, the bile container was changed at 1, 2, 3, 4, 5, 6, 12, and 24 h after the dose; for the
2169W94 studies, the container was changed at 8 and 24 h after the dose. Previous studies indicated that samples were stable
on ice for 24 h. Bile samples were stored at
20°C until analysis.
Analytical Procedure. Aliquots of cell lysate or bile samples containing 264W94 or 2169W94 were mixed with 2-fold volumes of ice-chilled acetonitrile and centrifuged to remove precipitated proteins. The supernatant was evaporated under nitrogen at room temperature and reconstituted in 100 µl of a 70/30 mixture of 50 mM ammonium acetate/acetonitrile/trifluoroacetic acid (95:5:0.1 v/v/v) and acetonitrile. The sample extracts were injected onto a Waters Symmetry C18 column (3.9 × 150 mm) and eluted by a 85:15 mixture of 50 mM ammonium acetate (pH 4.0) and acetonitrile; the percentage of acetonitrile was increased by a Waters 600E System Controller to 55% over a period of 20 min and then to 100% during the next 10 min. Radiocarbon that eluted from the HPLC was quantitated with an on-line radioactivity detector (Radiomatic Flo-One/Beta Radio-Chromatography Detector Series 500TR Series, Packard Instrument Co., Meriden, CT). The peaks of 264W94, 2169W94, and 2169W94 glucuronide were identified by comparing them with purified standard compound. Under these conditions, baseline separation of these three components was achieved. The concentration of the three components was determined by normalizing the eluted radioactivity in each peak to the total injected radioactivity.
Data Analysis. Uptake data were normalized to the protein content and expressed as mean ± S.D. from three to four separate preparations of hepatocytes. Statistical differences between mean values for the 10-min cumulative substrate uptake in the presence and absence of Ca2+ were determined by Student's t test. A P value of < .05 was considered significant.
In vivo biliary clearance, ClB (ml/min/kg body weight), was calculated according to eq. 1:
|
(1) |
|
(2) |
hematocrit]); Pollack et al.,
1990
|
(3) |
|
(4) |
| |
Results |
|---|
|
|
|---|
Cumulative Uptake in Cultured Hepatocytes. The cumulative uptake of inulin was negligible (less than 0.01% of initial added substrate) at all incubation times in either short- or long-term cultured hepatocytes (Fig. 1A and B). In the 3-h cultured hepatocytes, the cumulative uptake of salicylate, methotrexate, and [D-pen2,5]enkephalin was not significantly different in standard buffer and in Ca2+-free buffer (Figs. 2A, 3A, and 4A; p > .05). However, slightly higher cumulative uptake of taurocholate in standard buffer compared with Ca2+-free buffer was observed (Fig. 5A); at 10 min, the cumulative uptake in standard buffer was approximately 10% higher than in Ca2+-free buffer (p = .04). In 96-h cultured hepatocytes, extracellular Ca2+ had no effect on the cumulative uptake of salicylate (Fig. 2B, p > .05). However, the uptake of methotrexate, [D-pen2,5]enkephalin, and taurocholate in long-term cultured hepatocytes in standard buffer was significantly higher than in Ca2+-free buffer (Fig. 3B, 4B, and 5B; p < .05).
|
|
|
|
|
Relationship Between the Percentage of Dose Excreted in Bile in
Rats and Biliary Excretion Index in Cultured Hepatocytes.
Five model substrates representing a diverse spectrum of biliary
excretion properties were selected to examine the relationship between
the percentage of the dose excreted in bile in vivo in rats and the
biliary excretion index in sandwich-cultured hepatocytes. Information
regarding the percentage of the dose excreted in rat bile after i.v.
administration was obtained from the literature. The extent of inulin
and salicylate secretion into bile was negligible (Eriksson et al.,
1975
; Laznicek and and Laznickova, 1994
). Approximately 50 to 60% of a
22 µmol/kg methotrexate dose (Bremnes et al., 1989
; Masuda et al.,
1997
) and 70% of a 14.5 µmol/kg
[D-pen2,5]enkephalin dose (Chen and
Pollack, 1997
) were excreted into rat bile as unchanged drug in 1 h. Taurocholate biliary excretion was more rapid and extensive than
methotrexate and
[D-pen2,5]enkephalin. In 1 h,
virtually 100% of the dose (8.0 µmol/kg) was recovered in rat bile
(Inoue et al., 1985
).
|
Correlation of In Vitro and In Vivo Biliary Clearance.
The in vivo biliary clearance (ml/min/kg body weight) of inulin,
salicylate, methotrexate, and taurocholate was 0.035 (Eriksson et al.,
1975
), ~0 (Laznicek and Laznickova, 1994
), 12.1 (Masuda et al.,
1997
), and 29.8 (Inoue et al., 1985
), respectively. In vivo biliary
clearance of [D-pen2,5]enkephalin,
18.5 ml/min/kg, was calculated based on eq. 1 from the data reported by
Chen and Pollack (1997)
. Based on these in vivo biliary clearance
values, the intrinsic biliary clearance of inulin, salicylate,
methotrexate, [D-pen2,5]enkephalin,
and taurocholate was calculated from eq. 2 (0.04, 0, 17.3, 34.4, and
116.9 ml/min/kg, respectively). The in vitro biliary clearances of
inulin, salicylate, methotrexate,
[D-pen2,5]enkephalin, and
taurocholate, calculated from eq. 4 based on the 10-min cumulative
uptake data (Figs. 1B-5B) were ~0, ~0, 4.1 ± 1.0, 12.6 ± 2.2, and 56.2 ± 6.0 ml/min/kg, respectively. The in vivo
intrinsic biliary clearance correlated well with the in vitro biliary
clearance (r2 = 0.99) for the five model
compounds (Fig. 6B).
Comparison of In Vivo and In Vitro Biliary Excretion of 264W94 and
Its Metabolites.
The structures of compounds 264W94 and 2169W94 are presented
in Fig. 7. Compound 2169W94 is
the O-demethylated metabolite of 264W94 in rats and humans,
and can undergo further conjugation with
urindine-5'-diphosphoglucuronic acid to form a glucuronide conjugate
(Silver et al., 1996
).
|
|
|
| |
Discussion |
|---|
|
|
|---|
Previous studies have indicated that long-term primary rat
hepatocytes cultured between two layers of gelled collagen (sandwich configuration) maintain normal morphology, form extensive canalicular networks, and sustain liver-specific functions (Dunn et al., 1989
; 1991
; LeCluyse et al., 1996
). Recently, it has been demonstrated that
the biliary excretion of the nonfluorescent substrate, taurocholate, in
sandwich-cultured hepatocytes can be estimated as the difference in
cumulative uptake of taurocholate in monolayers preincubated in
standard buffer and in Ca2+-free buffer (Liu et
al., 1999a
).
The present study was undertaken to examine the relationship between in vitro and in vivo biliary excretion and to investigate the utility of this in vitro model to predict biliary excretion in vivo. Five nonfluorescent model substrates were used in these studies: inulin, salicylate, methotrexate, [D-pen2,5]enkephalin, and taurocholate. Inulin and salicylate were used as extracellular and simple diffusional markers, respectively. In addition, the utility of the cultured hepatocytes to predict biliary excretion of drug metabolites was assessed with the model compound 264W94 and its metabolite, 2169W94. Results indicate that the biliary excretion in sandwich-cultured hepatocytes correlates with in vivo biliary excretion. This in vitro model can be used to predict the biliary excretion of unchanged parent compound. Whether this in vitro model system can be used to predict the biliary excretion of metabolites depends upon the metabolic activity of the cultured hepatocytes.
It is well documented that Ca2+ is required to
maintain the integrity of tight junctions. Previous studies (Liu et
al., 1999b
) have demonstrated that a 10-min incubation of
hepatocyte monolayers in Ca2+-free buffer
disrupted the barrier function of tight junctions in the monolayers.
The disrupted tight junctions did not reseal within 10 min after
replacing the Ca2+-free buffer with standard
buffer. Therefore, a protocol of 10-min preincubation in
Ca2+-free buffer followed by uptake in standard
buffer was used in the present study.
Cumulative uptake was determined based on the total radioactivity in
the cell lysate. This approach was viable because the selected model
compounds are metabolically stable except salicylate. Salicylate is
metabolized in rat livers and excreted extensively in urine (Laznicek
and Laznickova, 1994
). Thus, it was not necessary to differentiate
salicylate from metabolites in the in vitro biliary excretion study.
In contrast to long-term cultured hepatocytes, intact bile canaliculi
are not present in short-term cultured hepatocytes (LeCluyse et al.,
1994
; Talamini et al., 1997
). Therefore, the cumulative uptake of
compounds in short-term cultured hepatocytes only revealed the effects
of Ca2+ on the transport properties. The
cumulative uptake of inulin, salicylate, methotrexate, and
[D-pen2,5]enkephalin did not differ
in the short-term cultured hepatocytes, suggesting that extracellular
Ca2+ modulation had no effect on the transport
properties of these model substrates. Interestingly, the cumulative
uptake of taurocholate in short-term cultured hepatocytes was slightly
higher in standard buffer than in Ca2+-free
buffer. This difference may be secondary to the existence of hepatocyte
couplets in the short-term cultures (Graf and Boyer, 1990
).
Biliary excretion of the five model substrates in long-term
cultured hepatocytes was consistent with their in vivo biliary excretion properties. Quantitation of biliary excretion in the cultured
hepatocytes using the biliary excretion index has been described
previously (Liu et al., 1999a
). The biliary excretion index
represents the percentage of retained substrate in the bile canaliculi.
Results indicate that compounds undergoing negligible biliary excretion
in vivo based on the percentage of the dose excreted in bile (e.g.,
inulin, salicylate) have a low biliary excretion index (~0) and
compounds that are more extensively excreted in bile in vivo (e.g.,
methotrexate,
[D-pen2,5]enkephalin, and
taurocholate) have a high biliary excretion index (~50%).
The relationship between the biliary excretion index and the percentage of the dose excreted in bile in vivo only reveals a categorical correlation. Methotrexate and [D-pen2,5]enkephalin represent compounds that are "highly" excreted in bile (approximately 60 and 70% of the i.v. dose was recovered in bile in 1 h, respectively). In contrast, taurocholate is "rapidly and extensively" excreted in biliary (almost all of the i.v. dose was excreted in bile in less than 1 h). The biliary excretion index can differentiate between compounds that undergo extensive versus negligible or low biliary excretion. However, the biliary excretion index does not appear to be able to differentiate between compounds that are highly excreted in bile, like methotrexate (biliary excretion index: ~55%) or [D-pen2,5]enkephalin (biliary excretion index: ~42%) and compounds that are "rapidly and extensively" excreted in bile, like taurocholate (biliary excretion index: ~56%). This limitation in the biliary excretion index may be due to the fact that this index is determined predominantly by the canalicular excretory function; the percentage of the i.v.-administered substrate excreted into bile in vivo is determined by sinusoidal uptake activity, canalicular excretory activity, as well as other competitive elimination processes.
Biliary clearance may represent a more appropriate parameter for
comparison of the relationship between in vivo and in vitro biliary
excretion. The in vivo biliary clearance was calculated in the present
study as the ratio of the amount excreted into bile at time T and the
plasma AUC between time 0 and time T. Because most of the administered
dose was eliminated at time T, the biliary clearance should approximate
the biliary clearance calculated from time 0 to infinity. Biliary
clearance calculated in this manner is a function of intrinsic biliary
clearance and the hepatic plasma flow rate. To eliminate the effects of
plasma flow, the intrinsic biliary clearance was calculated based on
the well-stirred model of hepatic disposition (Pang and Rowland, 1977
).
If the red blood cell distribution of a compound is known, plasma
clearance should be converted to blood clearance in eq. 1 and blood
flow instead of plasma flow should be used to calculate the intrinsic clearance in eq. 2. In vitro biliary clearance was calculated as the
ratio of the amount excreted into the canalicular networks in the
hepatocyte monolayers and the AUC in the incubation medium. In the
sandwich-cultured hepatocytes, the incubation medium was accessible to
all hepatocytes on the dish at the same time. Thus, the calculated in
vitro biliary clearance should represent the intrinsic biliary
clearance. However, because biliary excretion involves two processes,
uptake across the sinusoidal membrane and excretion across the
canalicular membrane, the true intrinsic biliary clearance should be
determined by transport across the canalicular membrane and calculated
based on intracellular substrate concentrations. Therefore, the in vivo
and in vitro "intrinsic" clearance values calculated in this study
should be considered as "apparent" intrinsic biliary clearance
values, which would be rate-limited by the slowest step in the process,
either sinusoidal uptake or canalicular excretion.
The correlation between in vitro biliary clearance and in vivo intrinsic biliary clearance was high (r2 = 0.99) for the five model substrates. According to the in vivo intrinsic biliary clearance, the five model substrates can be classified into three groups: compounds that are not excreted in bile (inulin and salicylate; ~0 ml/min/kg), compounds that are highly excreted in bile (methotrexate and [D-pen2,5]enkephalin; ~17.3 and ~34.4 ml/min/kg, respectively), and compounds that are rapidly and extensively excreted in bile (taurocholate; ~116.9 ml/min/kg). The estimated in vitro biliary clearance adequately differentiated between these three groups of compounds (~0, 4-13, and 56 ml/min/kg, respectively). These results suggest that the biliary clearance describes more accurately the relationship between in vivo and in vitro biliary excretion than the biliary excretion index.
To assess the utility of this in vitro model system to predict in vivo
biliary excretion of drug metabolites, the in vitro and in vivo biliary
excretion of 264W94, the O-demethylated metabolite (2169W94) and 2169W94 glucuronide were examined. In vitro studies conducted with rat and human liver microsomes, precision-cut liver slices, and cDNA expressed hepatic cytochrome P-450
isozymes indicated that 264W94 formed an O-demethylated metabolite at the 8-methoxy position. Among several cytochrome P-450
isozymes examined, CYP3A4 was the only one that played a major role in
the metabolism of 264W94 (Silver et al., 1996
). In vivo disposition
studies demonstrated that neither 264W94 nor its
O-demethylated metabolite, 2169W94, were excreted
in bile, but the 2169W94 glucuronide conjugate along with other unidentified metabolites were extensively excreted in bile. The
lack of biliary excretion of 264W94 in long-term sandwich-cultured hepatocytes was consistent with negligible in vivo biliary excretion of
264W94. In vivo, approximately 35% of 264W94 equivalent was excreted
in bile as metabolites in 1 h after i.v. administration of 264W94.
In cultured hepatocytes, however, the biliary excretion of 264W94
metabolites was negligible (Fig. 8B). This apparent discrepancy between
the in vivo and in vitro biliary excretion for the metabolites of
264W94 may be explained by differences in metabolic activities. In
vivo, 264W94 undergoes O-demethylation to form
2169W94; subsequently, 2169W94 is conjugated with
uridine-5'-diphosphoglucuronic acid to form 2169W94 glucuronide. This glucuronide conjugate accounts for 30% of the total
amount excreted in the bile. In the lysate of long-term cultured
hepatocytes, only ~3% of the total amount incubated was detected as
the 2169W94 glucuronide conjugate. These results indicate
that the long-term cultured hepatocytes were not capable of the
O-demethylation reaction. Consequently, negligible
glucuronide conjugate was formed and excreted in bile. However, after
incubation of the monolayers with 2169W94, the
O-demethylated metabolite of 264W94, 58.5% of
2169W94 was converted to glucuronide conjugates and
significant biliary excretion was observed in the cultured hepatocytes
(Fig. 9B). Evidently, phase I metabolic activities such as
O-demethylation deteriorate significantly, whereas the phase
II metabolic activities such as glucuronide conjugation are maintained,
at least in part, in the long-term sandwich-cultured hepatocytes. This
observation was consistent with previous studies indicating that
activities of phase II enzymes are better preserved in cultured
hepatocytes than those of phase I enzymes, although long-term cultured
hepatocytes lose both phase I and phase II enzyme activity (Niemann et
al., 1991
; Rogiers and Vercruysse, 1993
; LeCluyse et al., 1996
). The
present studies indicate that sandwich-cultured hepatocytes can be used
to predict in vivo biliary excretion of a substrate in its parent form.
The application of this in vitro model system to study and to predict
in vivo biliary excretion of metabolites requires consideration of the
status of metabolic activities in the monolayers.
The uncertainty in predicting the biliary excretion of drug metabolites should not limit the utility of this in vitro model as a screening tool for predicting the biliary excretion of drug candidates in vivo. This in vitro model may provide adequate information regarding the biliary clearance of a drug candidate in its parent from. The deterioration of phase I metabolic activity with maintenance of biliary transport may represent an advantage of this in vitro model system to differentiate the biliary excretion of parent drug versus metabolites.
Previous studies indicate that the extent to which individual P-450
enzymes are expressed in cultured hepatocytes depends greatly on the
medium and matrix conditions (Utesch et al., 1991
; Kocarek et al.,
1993
; Donato et al., 1994
; LeCluyse et al., 1996
). To predict the
biliary excretion of metabolites, culture conditions will need to be
optimized to maintain both hepatic transport as well as phase I and
phase II enzyme activities. In addition, recently it was reported that
extensive bile canalicular networks form in sandwich-cultured human
hepatocytes (Kono et al., 1997
). Whether biliary excretion in cultured
human hepatocytes correlates with biliary excretion in vivo in humans
is the subject of ongoing investigations.
In summary, results of the present study suggest that biliary excretion measured by the biliary excretion index and biliary clearance in sandwich-cultured rat hepatocytes correlates with in vivo biliary excretion in rats. Biliary clearance represents a useful indicator of in vivo biliary excretion. Application of this in vitro model to predict in vivo biliary excretion for drug metabolites is possible if the relevant metabolic activities in the in vitro model are maintained.
| |
Footnotes |
|---|
Received July 9, 1998; accepted February 24, 1999.
This work was supported in part by National Institutes of Health Grant GM41935. X.L. was supported in part by a fellowship sponsored by Glaxo Wellcome, Inc.
Send reprint requests to: Dr. Kim L.R. Brouwer, Pharm.D., Ph.D., Division of Drug Delivery and Disposition, School of Pharmacy, CB# 7360, Beard Hall, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7360. E-mail: kbrouwer{at}unc.edu
| |
Abbreviations |
|---|
Abbreviations used are: DMEM, Dulbecco's modified Eagle's medium.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
J. H. Ansede, M. R. Wright, R. L. St. Claire III, R. W. Hart, H. A. Gefroh, and K. R. Brouwer Characterization of Sandwich-Cultured Hepatocytes As an in Vitro Model to Assess the Hepatobiliary Disposition of Copper Drug Metab. Dispos., May 1, 2009; 37(5): 969 - 976. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Feng, J. J. Xu, Y.-A. Bi, R. Mireles, R. Davidson, D. B. Duignan, S. Campbell, V. E. Kostrubsky, M. C. Dunn, A. R. Smith, et al. Role of Hepatic Transporters in the Disposition and Hepatotoxicity of a HER2 Tyrosine Kinase Inhibitor CP-724,714 Toxicol. Sci., April 1, 2009; 108(2): 492 - 500. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Abe, A. S. Bridges, and K. L. R. Brouwer Use of Sandwich-Cultured Human Hepatocytes to Predict Biliary Clearance of Angiotensin II Receptor Blockers and HMG-CoA Reductase Inhibitors Drug Metab. Dispos., March 1, 2009; 37(3): 447 - 452. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. K. Wolf, K. R. Brouwer, G. M. Pollack, and K. L. R. Brouwer Effect of Albumin on the Biliary Clearance of Compounds in Sandwich-Cultured Rat Hepatocytes Drug Metab. Dispos., October 1, 2008; 36(10): 2086 - 2092. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Abe, A. S. Bridges, W. Yue, and K. L. R. Brouwer In Vitro Biliary Clearance of Angiotensin II Receptor Blockers and 3-Hydroxy-3-methylglutaryl-Coenzyme A Reductase Inhibitors in Sandwich-Cultured Rat Hepatocytes: Comparison with in Vivo Biliary Clearance J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 983 - 990. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Govindarajan, C. J. Endres, D. Whittington, E. LeCluyse, M. Pastor-Anglada, C.-M. Tse, and J. D. Unadkat Expression and hepatobiliary transport characteristics of the concentrative and equilibrative nucleoside transporters in sandwich-cultured human hepatocytes Am J Physiol Gastrointest Liver Physiol, September 1, 2008; 295(3): G570 - G580. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Fukuda, R. Ohashi, M. Tsuda-Tsukimoto, and I. Tamai Effect of Plasma Protein Binding on in Vitro-in Vivo Correlation of Biliary Excretion of Drugs Evaluated by Sandwich-Cultured Rat Hepatocytes Drug Metab. Dispos., July 1, 2008; 36(7): 1275 - 1282. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Kalgutkar, B. Feng, H. T. Nguyen, K. S. Frederick, S. D. Campbell, H. L. Hatch, Y.-A. Bi, D. C. Kazolias, R. E. Davidson, R. J. Mireles, et al. Role of Transporters in the Disposition of the Selective Phosphodiesterase-4 Inhibitor (+)-2-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic Acid in Rat and Human Drug Metab. Dispos., November 1, 2007; 35(11): 2111 - 2118. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-a. Bi, D. Kazolias, and D. B. Duignan Use of Cryopreserved Human Hepatocytes in Sandwich Culture to Measure Hepatobiliary Transport Drug Metab. Dispos., September 1, 2006; 34(9): 1658 - 1665. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Z. Turncliff, K. A. Hoffmaster, J. C. Kalvass, G. M. Pollack, and K. L. R. Brouwer Hepatobiliary Disposition of a Drug/Metabolite Pair: Comprehensive Pharmacokinetic Modeling in Sandwich-Cultured Rat Hepatocytes J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 881 - 889. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Liu, Y. Cui, A. Y. Chung, Y. Shitara, Y. Sugiyama, D. Keppler, and K. S. Pang Vectorial Transport of Enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in Rat and Human Livers J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 395 - 402. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Engtrakul, R. S. Foti, T. J. Strelevitz, and M. B. Fisher ALTERED AZT (3'-AZIDO-3'-DEOXYTHYMIDINE) GLUCURONIDATION KINETICS IN LIVER MICROSOMES AS AN EXPLANATION FOR UNDERPREDICTION OF IN VIVO CLEARANCE: COMPARISON TO HEPATOCYTES AND EFFECT OF INCUBATION ENVIRONMENT Drug Metab. Dispos., November 1, 2005; 33(11): 1621 - 1627. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Lengyel, Z. Veres, P. Szabo, L. Vereczkey, and K. Jemnitz CANALICULAR AND SINUSOIDAL DISPOSITION OF BILIRUBIN MONO- AND DIGLUCURONIDES IN SANDWICH-CULTURED HUMAN AND RAT PRIMARY HEPATOCYTES Drug Metab. Dispos., September 1, 2005; 33(9): 1355 - 1360. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Zhang, X. Tian, P. Chandra, and K. L. R. Brouwer Role of Glycosylation in Trafficking of Mrp2 in Sandwich-Cultured Rat Hepatocytes Mol. Pharmacol., April 1, 2005; 67(4): 1334 - 1341. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. P. Annaert and K. L. R. Brouwer ASSESSMENT OF DRUG INTERACTIONS IN HEPATOBILIARY TRANSPORT USING RHODAMINE 123 IN SANDWICH-CULTURED RAT HEPATOCYTES Drug Metab. Dispos., March 1, 2005; 33(3): 388 - 394. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Hoffmaster, M. J. Zamek-Gliszczynski, G. M. Pollack, and K. L. R. Brouwer MULTIPLE TRANSPORT SYSTEMS MEDIATE THE HEPATIC UPTAKE AND BILIARY EXCRETION OF THE METABOLICALLY STABLE OPIOID PEPTIDE [D-PENICILLAMINE2,5]ENKEPHALIN Drug Metab. Dispos., February 1, 2005; 33(2): 287 - 293. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C. Kemp, M. J. Zamek-Gliszczynski, and K. L. R. Brouwer Xenobiotics Inhibit Hepatic Uptake and Biliary Excretion of Taurocholate in Rat Hepatocytes Toxicol. Sci., February 1, 2005; 83(2): 207 - 214. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Tian, M. J. Zamek-Gliszczynski, P. Zhang, and K. L. R. Brouwer Modulation of Multidrug Resistance-Associated Protein 2 (Mrp2) and Mrp3 Expression and Function with Small Interfering RNA in Sandwich-Cultured Rat Hepatocytes Mol. Pharmacol., October 1, 2004; 66(4): 1004 - 1010. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Z. Turncliff, P. J. Meier, and K. L. R. Brouwer EFFECT OF DEXAMETHASONE TREATMENT ON THE EXPRESSION AND FUNCTION OF TRANSPORT PROTEINS IN SANDWICH-CULTURED RAT HEPATOCYTES Drug Metab. Dispos., August 1, 2004; 32(8): 834 - 839. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Zamek-Gliszczynski, H. Xiong, N. J. Patel, R. Z. Turncliff, G. M. Pollack, and K. L. R. Brouwer Pharmacokinetics of 5 (and 6)-Carboxy-2',7'-Dichlorofluorescein and Its Diacetate Promoiety in the Liver J. Pharmacol. Exp. Ther., February 1, 2003; 304(2): 801 - 809. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. P. Annaert, R. Z. Turncliff, C. L. Booth, D. R. Thakker, and K. L. R. Brouwer P-Glycoprotein-Mediated In Vitro Biliary Excretion in Sandwich-Cultured Rat Hepatocytes Drug Metab. Dispos., October 1, 2001; 29(10): 1277 - 1283. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||